Premium
Cidofovir induces an increase in levels of low‐risk and high‐risk HPV E6
Author(s) -
Donne Adam J.,
Hampson Lynne,
He Xiaotong T.,
Rothera Michael P.,
Homer Jarrod J.,
Hampson Ian N.
Publication year - 2009
Publication title -
head and neck
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.012
H-Index - 127
eISSN - 1097-0347
pISSN - 1043-3074
DOI - 10.1002/hed.21043
Subject(s) - cidofovir , transfection , virology , cancer research , recurrent respiratory papillomatosis , complementary dna , biology , gene , microbiology and biotechnology , virus , medicine , oncology , human papillomavirus , genetics
Background. Cidofovir is a nucleoside analogue that is used off‐license to treat recurrent respiratory papillomatosis (RRP) caused by HPV6/11. However, the effect of this drug upon low‐risk HPV 6/11 gene expression is unknown.Methods. The expression of E6 was evaluated by RT‐PCR in HPV−ve C33A cervical carcinoma cells stably transfected with both low‐ and high‐risk HPV E6 cDNA's and in SiHa (HPV16+ve) cervical carcinoma cells after treatment with 2 doses and durations of exposure to cidofovir.Results. Compared to the vector only transcript, E6 RNA levels showed an 8‐fold increase in low‐risk and 20‐fold increase in high‐risk E6‐expressing cells. High‐risk E6 protein levels were also detected by Western blot in cidofovir‐treated C33A Type16 E6‐transfected cells.Conclusion. These data may indicate a potential rationale for increased risk of genetic instability and thus transformation due to drug‐induced increase in the level of E6. © 2009 Wiley Periodicals, Inc. Head Neck, 2009